Previous 10 |
Tarsus Pharmaceuticals (TARS) announces that it has received the written minutes of the (Type C) meeting held on December 8 with the FDA on specific NDA submission requirements for TP-03.NDA relates to TP-03 as a treatment for Demodex blepharitis, a common ocular condition with 45% or 9M...
IRVINE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, startin...
Gainers: Anterix (ATEX) +67%.NantKwest (NK) +55%.500.com Limited (WBAI) +51%.Editas Medicine (EDIT) +47%.EyeGate Pharmaceuticals (EYEG) +45%.Organovo Holdings (ONVO) +36%.Nuverra Environmental Solutions (NES) +33%.RealPage (RP) +29%.Agios Pharmaceuticals (AGIO) +29%.CuriosityStream (CURI...
Gainers: EyeGate Pharmaceuticals (EYEG) +78%, Editas Medicine (EDIT) +42%, NantKwest (NK) +30%, Liminal BioSciences (LMNL) +29%, Agios Pharmaceuticals (AGIO) +24%.Losers: Scopus BioPharma (SCPS) -17%, uniQure (QURE) -16%, C...
IRVINE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, startin...
Gainers: Anchiano Therapeutics (ANCN) +142%.BioCardia (BCDA) +87%.Prevail Therapeutics (PRVL) +81%.Solid Biosciences (SLDB) +36%.OncoCyte (OCX) +24%.Bridgetown (BTWN) +23%.Contango Oil & Gas (MCF) +22%.Immutep (IMMP) +22%.MicroVision (MVIS) +20%.Sio Gene Therapies (SIOX) +1...
IRVINE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, startin...
IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus” NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly tr...
IRVINE, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus”), a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic c...
News, Short Squeeze, Breakout and More Instantly...
Tarsus Pharmaceuticals Inc. Company Name:
TARS Stock Symbol:
NASDAQ Market:
Tarsus Pharmaceuticals Inc. Website:
2024-06-03 08:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in t...
2024-05-13 07:00:04 ET Oren Livnat from H.C. Wainwright issued a price target of $61.00 for TARS on 2024-05-13 06:01:00. The adjusted price target was set to $61.00. At the time of the announcement, TARS was trading at $37. TARS currently trades -5.98% versus its 52 week...